Development of Novel NPC1-Targeting Autophagy Inhibitors for the Treatment of Uveal Melanoma

Background: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and up to 50% of patients develop liver metastases. Metastatic UM responds poorly to conventional chemotherapy and currently available immunotherapies, highlighting the need for new therapeutic strategies. Because UM cells rely on lysosome-dependent stress-response pathways, including autophagy, we evaluated previously reported betulinic acid (BetA) derivatives and identified ALS-997 as a potent inhibitor of autophagic flux in UM cells. Methods: The anticancer activity of BetA derivatives was evaluated using the NCI-60 cancer cell line panel and WST-1 viability assays in UM cell lines and normal human melanocytes. Effects on autophagy and lysosomal function were assessed by western blotting for mTOR and autophagy associated proteins, LysoTracker Green imaging, and filipin III/LAMP2 staining. Apoptosis was evaluated by PARP cleavage and caspase-3 cleavage. The interaction of ALS-997 with Niemann-Pick disease type C1 (NPC1) was examined using a cellular thermal shift assay and computational molecular docking. NPC1 expression in UM cells and normal melanocytes was compared by quatitative PCR and western blotting. Results: ALS-997 preferentially reduced the viability of UM cell relative to normal melanocytes. Treatment with ALS-997 disrupted autophagic flux and lysosomal function, induced lysosomal cholesterol accumulation, and activated apoptotic signaling. ALS-997 also altered the thermal stability of NPC1, supporting cellular target engagement, while molecular docking predicted a direct interaction between ALS-997 and NPC1. NPC1 expression was higher in UM cells than in normal melanocytes. Conclusions: ALS-997 is a BetA-derived compound that disrupts lysosomal cholesterol homeostasis and autophagic flux, leading to apoptosis in UM cells. These findings support NPC1 as a potential therapeutic target in UM.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766269
Primary Topic
Ocular Oncology and Treatments
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Development of Novel NPC1-Targeting Autophagy Inhibitors for the Treatment of Uveal Melanoma

Michael T. Flavin, Geyi Li, Satoshi Endo, Michael J. Heiferman et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Ocular Oncology and Treatments
preprint

Development of Novel NPC1-Targeting Autophagy Inhibitors for the Treatment of Uveal Melanoma

Michael T. Flavin, Geyi Li, Satoshi Endo, Michael J. Heiferman, Kaori H. Yamada, Sarah Scoles, Yudai Kudo, Jia Yu Ning
preprint en

Abstract

Background: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and up to 50% of patients develop liver metastases. Metastatic UM responds poorly to conventional chemotherapy and currently available immunotherapies, highlighting the need for new therapeutic strategies. Because UM cells rely on lysosome-dependent stress-response pathways, including autophagy, we evaluated previously reported betulinic acid (BetA) derivatives and identified ALS-997 as a potent inhibitor of autophagic flux in UM cells. Methods: The anticancer activity of BetA derivatives was evaluated using the NCI-60 cancer cell line panel and WST-1 viability assays in UM cell lines and normal human melanocytes. Effects on autophagy and lysosomal function were assessed by western blotting for mTOR and autophagy associated proteins, LysoTracker Green imaging, and filipin III/LAMP2 staining. Apoptosis was evaluated by PARP cleavage and caspase-3 cleavage. The interaction of ALS-997 with Niemann-Pick disease type C1 (NPC1) was examined using a cellular thermal shift assay and computational molecular docking. NPC1 expression in UM cells and normal melanocytes was compared by quatitative PCR and western blotting. Results: ALS-997 preferentially reduced the viability of UM cell relative to normal melanocytes. Treatment with ALS-997 disrupted autophagic flux and lysosomal function, induced lysosomal cholesterol accumulation, and activated apoptotic signaling. ALS-997 also altered the thermal stability of NPC1, supporting cellular target engagement, while molecular docking predicted a direct interaction between ALS-997 and NPC1. NPC1 expression was higher in UM cells than in normal melanocytes. Conclusions: ALS-997 is a BetA-derived compound that disrupts lysosomal cholesterol homeostasis and autophagic flux, leading to apoptosis in UM cells. These findings support NPC1 as a potential therapeutic target in UM.

bioRxiv (Cold Spring Harbor Laboratory)
University of Illinois Chicago (US), Gifu University (JP)
American Cancer Society
Good health and well-being
Ocular Oncology and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon